Pleurodesis

Carla Lamb; Andrew Li; Dhaval Thakkar; Pyng Lee

doi:10.1055/s-0039-1693997

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2019; 40(03): 375-385
DOI: 10.1055/s-0039-1693997

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Pleurodesis

Carla Lamb

¹Department of Pulmonary and Critical Care Medicine, Lahey Hospital and Medical Center, Boston, Massachusetts

,

Andrew Li

²Division of Respiratory and Critical Care Medicine, National University Hospital, Singapore

,

Dhaval Thakkar

¹Department of Pulmonary and Critical Care Medicine, Lahey Hospital and Medical Center, Boston, Massachusetts

,

Pyng Lee

²Division of Respiratory and Critical Care Medicine, National University Hospital, Singapore

› Author Affiliations

Abstract

Symptomatic pleural disease, specifically malignant pleural effusion, refractory benign pleural effusion, and pneumothoraces are common diseases that often require therapeutic interventions. The spectrum of management strategies often includes selection of a chemical pleurodesis agent administered in combination with an indwelling pleural catheter or chest tube.

Additionally, there is a role for minimally invasive techniques which include medical thoracoscopy or more advanced video-assisted thoracoscopic approaches. Ongoing clinical trials continue to evolve best practices regarding the optimal sclerosant agents and procedural approaches in the management of these diseases.

Keywords

pleural effusion - malignant pleural effusion - pneumothorax - pleurodesis - talc - indwelling pleural catheter - chest tube - medical thoracoscopy - video-assisted thoracoscopic surgery

Full Text

References

References
1 Light RW. Pleural Diseases. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013
2 Lee YCG, Teixeira LR, Devin CJ. , et al. Transforming growth factor-beta2 induces pleurodesis significantly faster than talc. Am J Respir Crit Care Med 2001; 163 (3, Pt 1): 640-644
3 Antony VB, Nasreen N, Mohammed KA. , et al. Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis. Chest 2004; 126 (05) 1522-1528
4 Hojski A, Leitgeb M, Crnjac A. Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study. Radiol Oncol 2015; 49 (04) 386-394
5 MacDuff A, Arnold A, Harvey J. ; BTS Pleural Disease Guideline Group. Management of spontaneous pneumothorax: British Thoracic Society pleural disease guideline 2010. Thorax 2010; 65 (Suppl. 02) ii18-ii31
6 Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 2010; 65 (Suppl. 02) ii32-ii40
7 Lee P, Folch E. Thoracoscopy: advances and increasing role of interventional pulmonologists. Semin Respir Crit Care Med 2018; 39 (06) 693-703
8 Janssen JP, Collier G, Astoul P. , et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 2007; 369 (9572): 1535-1539
9 Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev 2016; (05) CD010529
10 Ahmed L, Ip H, Rao D, Patel N, Noorzad F. Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: retrospective case series of a novel clinical pathway. Chest 2014; 146 (06) e190-e194
11 Katlic MR. Video-assisted thoracic surgery utilizing local anesthesia and sedation. Eur J Cardiothorac Surg 2006; 30 (03) 529-532
12 Villanueva AG, Gray Jr AW, Shahian DM, Williamson WA, Beamis Jr JF. Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax 1994; 49 (01) 23-25
13 Dryzer SR, Allen ML, Strange C, Sahn SA. A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest 1993; 104 (06) 1763-1766
14 Bethune N. Pleural poudrage: new technique for deliberate production of pleural adhesions as preliminary to lobectomy. J Thorac Surg 1935; 4 (01) 251
15 Jones GR. Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis. Thorax 1969; 24 (01) 69-73
16 Lee YC, Baumann MH, Maskell NA. , et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Chest 2003; 124 (06) 2229-2238
17 Gonzalez AV, Bezwada V, Beamis Jr JF, Villanueva AG. Lung injury following thoracoscopic talc insufflation: experience of a single North American center. Chest 2010; 137 (06) 1375-1381
18 Maskell NA, Lee YC, Gleeson FV, Hedley EL, Pengelly G, Davies RJ. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170 (04) 377-382
19 Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis. PLoS One 2014; 9 (01) e87060
20 Bhatnagar R, Laskawiec-Szkonter M, Piotrowska HE. , et al. Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry (TAPPS trial): protocol of an open-label randomised controlled trial. BMJ Open 2014; 4 (11) e007045
21 Feller-Kopman DJ, Reddy CB, DeCamp MM. , et al. Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med 2018; 198 (07) 839-849
22 Mummadi S, Kumbam A, Hahn PY. Malignant pleural effusions and the role of talc poudrage and talc slurry: a systematic review and meta-analysis. (Version 2). F1000 Res 2015; 3: 254
23 Fysh ET, Tan SK, Read CA. , et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax 2013; 68 (06) 594-596
24 Dryzer SR, Allen ML, Strange C, Sahn SA. A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest 1993; 104 (06) 1763-1766
25 Putnam Jr JB, Light RW, Rodriguez RM. , et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999; 86 (10) 1992-1999
26 Heffner JE, Standerfer RJ, Torstveit J, Unruh L. Clinical efficacy of doxycycline for pleurodesis. Chest 1994; 105 (06) 1743-1747
27 Haddad FJ, Younes RN, Gross JL, Deheinzelin D. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial. World J Surg 2004; 28 (08) 749-753 , discussion 753–754
28 Agarwal R, Khan A, Aggarwal AN, Gupta D. Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis. Indian J Med Res 2012; 135: 297-304
29 Wagenfeld L, Zeitz O, Richard G. Visual loss after povidone-iodine pleurodesis. N Engl J Med 2007; 357 (12) 1264-1265
30 Mohsen TA, Zeid AA, Meshref M. , et al. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial. Eur J Cardiothorac Surg 2011; 40 (02) 282-286
31 Brock RC. Recurrent and chronic spontaneous pneumothorax. Thorax 1948; 3 (02) 88-111
32 Paschoalini MdaS, Vargas FS, Marchi E. , et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 2005; 128 (02) 684-689
33 Menna C, Andreetti C, Ibrahim M. , et al. The effect of silver nitrate pleurodesis after a failed thoracoscopic talc poudrage. BioMed Res Int 2013; 2013: 295890
34 Terra RM, Bellato RT, Teixeira LR, Chate RC, Pego-Fernandes PM. Safety and systemic consequences of pleurodesis with three different doses of silver nitrate in patients with malignant pleural effusion. Respiration 2015; 89 (04) 276-283
35 Vargas FS, Carmo AO, Teixeira LR. A new look at old agents for pleurodesis: nitrogen mustard, sodium hydroxide, and silver nitrate. Curr Opin Pulm Med 2000; 6 (04) 281-286
36 Bhatnagar R, Zahan-Evans N, Kearney C. , et al. A novel drug-eluting indwelling pleural catheter for the management of malignant effusions. Am J Respir Crit Care Med 2018; 197 (01) 136-138
37 Okamoto H, Shoin S, Koshimura S, Shimizu R. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. Jpn J Microbiol 1967; 11 (04) 323-326
38 Matsubara N, Itoh K, Mukai H, Nagai S. Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 cases. Int J Clin Oncol 2012; 17 (05) 470-476
39 Mochizuki E, Mochizuka Y, Oishi K. , et al. P3.01-73 Talc versus minocycline and OK-432 pleurodesis for malignant pleural effusion. J Thorac Oncol 2018; 13 (10) S895
40 Nohara K, Takada K, Kojima E. , et al. A propensity score-matched comparison of the efficacies of OK-432 and talc slurry for pleurodesis for malignant pleural effusion induced by lung adenocarcinoma. Respir Investig 2016; 54 (05) 341-346
41 Yokoe N, Katsuda E, Kosaka K. , et al. Interstitial lung disease after pleurodesis for malignant pleural effusion. Intern Med 2017; 56 (14) 1791-1797
42 Webb HE, Oaten SW, Pike CP. Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum. BMJ 1978; 1 (6109): 338-340
43 Millar JW, Hunter AM, Horne NW. Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions. Thorax 1980; 35 (11) 856-858
44 McLeod DT, Calverley PM, Millar JW, Horne NW. Further experience of Corynebacterium parvum in malignant pleural effusion. Thorax 1985; 40 (07) 515-518
45 Bilaçeroğlu S, Cağirici U, Perim K, Ozacar R. Corynebacterium parvum pleurodesis and survival is not significantly influenced by pleural pH and glucose level. Monaldi Arch Chest Dis 1998; 53 (01) 14-22
46 Shehata SM, Sileem AE, El-Fakharany KM. Pleural fluid CRP, LDH, and pH as predictors of successful pleurodesis in malignant pleural effusions. Egypt J Chest Dis Tuberc 2015; 64: 593-599
47 Salomaa ER, Pulkki K, Helenius H. Pleurodesis with doxycycline or Corynebacterium parvum in malignant pleural effusion. Acta Oncol 1995; 34 (01) 117-121
48 Cho JS, Na KJ, Lee Y. , et al. Chemical pleurodesis using mistletoe extraction (ABNOVAviscum(®) Injection) for malignant pleural effusion. Ann Thorac Cardiovasc Surg 2016; 22 (01) 20-26
49 Stumpf C, Büssing A. Stimulation of antitumour immunity by intrapleural instillation of a Viscum album L. extract. Anticancer Drugs 1997; 8 (Suppl. 01) S23-S26
50 Eom JS, Ahn HY, Mok JH. , et al. Pleurodesis using mistletoe extract delivered via a spray catheter during semirigid pleuroscopy for managing symptomatic malignant pleural effusion. Respiration 2018; 95 (03) 177-181
51 Keeratichananont W, Limthon T, Keeratichananont S. Efficacy and safety profile of autologous blood versus tetracycline pleurodesis for malignant pleural effusion. Ther Adv Respir Dis 2015; 9 (02) 42-48
52 Keeratichananont W, Kaewdech A, Keeratichananont S. Efficacy and safety profile of autologous blood versus talc pleurodesis for malignant pleural effusion: a randomized controlled trial. Ther Adv Respir Dis 2018; 12: 1753466618816625
53 Manley K, Coonar A, Wells F, Scarci M. Blood patch for persistent air leak: a review of the current literature. Curr Opin Pulm Med 2012; 18 (04) 333-338
54 Rahman NM, Pepperell J, Rehal S. , et al. Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. JAMA 2015; 314 (24) 2641-2653
55 Thethi I, Ramirez S, Shen W. , et al. Effect of chest tube size on pleurodesis efficacy in malignant pleural effusion: a meta-analysis of randomized controlled trials. J Thorac Dis 2018; 10 (01) 355-362
56 Mager HJ, Maesen B, Verzijlbergen F, Schramel F. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer 2002; 36 (01) 77-81
57 Xie C, Teixeira LR, McGovern JP, Light RW. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am J Respir Crit Care Med 1998; 157 (5, Pt 1): 1441-1444
58 Goodman A, David CW. Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: A randomised trial. Lung Cancer 2006; 54 (01) 51-55
59 Reddy C, Ernst A, Lamb C, Feller-Kopman D. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest 2011; 139 (06) 1419-1423
60 de Campos JR, Vargas FS, de Campos Werebe E. , et al. Thoracoscopy talc poudrage : a 15-year experience. Chest 2001; 119 (03) 801-806
61 Baumgartner WA, Mark JB. The use of thoracoscopy in the diagnosis of pleural disease. Arch Surg 1980; 115 (04) 420-421
62 Mack MJ, Aronoff RJ, Acuff TE, Douthit MB, Bowman RT, Ryan WH. Present role of thoracoscopy in the diagnosis and treatment of diseases of the chest. Ann Thorac Surg 1992; 54 (03) 403-408 , discussion 407–409
63 Fitzgerald DB, Koegelenberg CFN, Yasufuku K, Lee YCG. Surgical and non-surgical management of malignant pleural effusions. Expert Rev Respir Med 2018; 12 (01) 15-26
64 Barbetakis N, Asteriou C, Papadopoulou F. , et al. Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases. J Cardiothorac Surg 2010; 5: 27
65 Stammberger U, Steinacher C, Hillinger S, Schmid RA, Kinsbergen T, Weder W. Early and long-term complaints following video-assisted thoracoscopic surgery: evaluation in 173 patients. Eur J Cardiothorac Surg 2000; 18 (01) 7-11
66 Taghizadeh N, Fortin M, Tremblay A. US hospitalizations for malignant pleural effusions: data from the 2012 National inpatient sample. Chest 2017; 151 (04) 845-854
67 Marel M, Zrůstová M, Stasný B, Light RW. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest 1993; 104 (05) 1486-1489
68 Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 2015; 20 (04) 654-659
69 Gurung P, Goldblatt MR, Huggins JT. , et al. Pleural fluid characteristics of paramalignant effusion. Chest 2009; 136 (04) 44S
70 Clive AO, Kahan BC, Hooper CE. , et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 2014; 69 (12) 1098-1104
71 Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest 2000; 117 (01) 87-95
72 Santos PS, Marques MA, Cruz C, Monteiro H, Fradinho F. Predictors of talc slurry pleurodesis success in patients with malignant pleural effusions. Rev Port Pneumol (2006) 2017; 23 (04) 216-220
73 Psallidas I, Kanellakis NI, Gerry S. , et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol 2018; 19 (07) 930-939
74 Chen J, Li Z, Xu N, Zhang X, Wang Y, Lin D. Efficacy of medical thoracoscopic talc pleurodesis in malignant pleural effusion caused by different types of tumors and different pathological classifications of lung cancer. Int J Clin Exp Med 2015; 8 (10) 18945-18953
75 Korsic M, Badovinac S, Cucevic B, Janevski Z. Talc pleurodesis improves survival of patients with malignant pleural effusions: case-control study. Wien Klin Wochenschr 2015; 127 (23–24): 963-969
76 Bintcliffe OJ, Lee GY, Rahman NM, Maskell NA. The management of benign non-infective pleural effusions. Eur Respir Rev 2016; 25 (141) 303-316
77 Vargas FS, Milanez JRC, Filomeno LTB, Fernandez A, Jatene A, Light RW. Intrapleural talc for the prevention of recurrence in benign or undiagnosed pleural effusions. Chest 1994; 106 (06) 1771-1775
78 Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117 (05) 1404-1409
79 Patil M, Dhillon SS, Attwood K, Saoud M, Alraiyes AH, Harris K. Management of benign pleural effusions using indwelling pleural catheters – a systematic review and meta-analysis. Chest 2017; 151 (03) 626-635
80 Bramley K, DeBiasi E, Puchalski J. Indwelling pleural catheter placement for nonmalignant pleural effusions. Semin Respir Crit Care Med 2018; 39 (06) 713-719
81 Porcel JM. Management of refractory hepatic hydrothorax. Curr Opin Pulm Med 2014; 20 (04) 352-357
82 Light RW. New treatment for hepatic hydrothorax?. Ann Am Thorac Soc 2016; 13 (06) 773-774
83 Hou F, Qi X, Guo X. Effectiveness and safety of pleurodesis for hepatic hydrothorax: a systematic review and meta-analysis. Dig Dis Sci 2016; 61 (11) 3321-3334
84 Singh A, Bajwa A, Shujaat A. Evidence-based review of the management of hepatic hydrothorax. Respiration 2013; 86 (02) 155-173
85 Chen A, Massoni J, Jung D, Crippin J. Indwelling tunneled pleural catheters for the management of hepatic hydrothorax - a pilot study. Ann Am Thorac Soc 2016; 13 (06) 862-866
86 Kniese C, Diab K, Ghabril M, Bosslet G. Indwelling pleural catheters in hepatic hydrothorax – a single-center series of outcomes and complications. Chest 2019; 155 (02) 307-314
87 Shojaee S, Rahman N, Haas K. , et al. Indwelling tunneled pleural catheters for refractory hepatic hydrothorax in patients with cirrhosis. Chest 2019; 155 (03) 546-553
88 Yancy CW, Jessup M, Bozkurt B. , et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. Circulation 2017; 136 (06) e137-e161
89 Majid A, Kheir F, Fashjian M. , et al. Tunneled pleural catheter placement with and without talc poudrage for treatment of pleural effusions due to congestive heart failure. Ann Am Thorac Soc 2016; 13 (02) 212-216
90 McGrath EE, Blades Z, Anderson PB. Chylothorax: aetiology, diagnosis and therapeutic options. Respir Med 2010; 104 (01) 1-8
91 Tschopp JM, Bintcliffe O, Astoul P. , et al. ERS task force statement: diagnosis and treatment of primary spontaneous pneumothorax. Eur Respir J 2015; 46 (02) 321-335
92 Dugan KC, Laxmanan B, Murgu S, Hogarth DK. Management of persistent air leaks. Chest 2017; 152 (02) 417-423
93 Bintcliffe OJ, Hallifax RJ, Edey A. , et al. Spontaneous pneumothorax: time to rethink management?. Lancet Respir Med 2015; 3 (07) 578-588
94 Lesur O, Delorme N, Fromaget JM, Bernadac P, Polu JM. Computed tomography in the etiologic assessment of idiopathic spontaneous pneumothorax. Chest 1990; 98 (02) 341-347
95 Vanderschueren RG. The role of thoracoscopy in the evaluation and management of pneumothorax. Hai 1990; 168 (Suppl): 1122-1125
96 Casali C, Stefani A, Ligabue G. , et al. Role of blebs and bullae detected by high-resolution computed tomography and recurrent spontaneous pneumothorax. Ann Thorac Surg 2013; 95 (01) 249-255
97 Noppen M, Dekeukeleire T, Hanon S. , et al. Fluorescein-enhanced autofluorescence thoracoscopy in patients with primary spontaneous pneumothorax and normal subjects. Am J Respir Crit Care Med 2006; 174 (01) 26-30
98 Chen JS, Chan WK, Tsai KT. , et al. Simple aspiration and drainage and intrapleural minocycline pleurodesis versus simple aspiration and drainage for the initial treatment of primary spontaneous pneumothorax: an open-label, parallel-group, prospective, randomised, controlled trial. Lancet 2013; 381 (9874): 1277-1282
99 Adewole OO, De Keukeleire T, Phillips AS, Erhabor G, Noppen M. Effectiveness of thoracoscopic talc pleurodesis in the management of complicated spontaneous pneumothorax. J Bronchology Interv Pulmonol 2015; 22 (01) 48-51
100 Treasure T. Minimally invasive surgery for pneumothorax: the evidence, changing practice and current opinion. J R Soc Med 2007; 100 (09) 419-422
101 Barker A, Maratos EC, Edmonds L, Lim E. Recurrence rates of video-assisted thoracoscopic versus open surgery in the prevention of recurrent pneumothoraces: a systematic review of randomised and non-randomised trials. Lancet 2007; 370 (9584): 329-335
102 Waller DA. Video-assisted thoracoscopic surgery for spontaneous pneumothorax--a 7-year learning experience. Ann R Coll Surg Engl 1999; 81 (06) 387-392
103 Vohra HA, Adamson L, Weeden DF. Does video-assisted thoracoscopic pleurectomy result in better outcomes than open pleurectomy for primary spontaneous pneumothorax?. Interact Cardiovasc Thorac Surg 2008; 7 (04) 673-677
104 Loubani M, Lynch V. Video assisted thoracoscopic bullectomy and acromycin pleurodesis: an effective treatment for spontaneous pneumothorax. Respir Med 2000; 94 (09) 888-890
105 Hallifax RJ, Yousuf A, Jones HE, Corcoran JP, Psallidas I, Rahman NM. Effectiveness of chemical pleurodesis in spontaneous pneumothorax recurrence prevention: a systematic review. Thorax 2017; 72 (12) 1121-1131
106 Venuta F, Mantovani S, Diso D, Poggi C, Anile M. The surgical point of view about persistent air leaks. Chest 2017; 152 (06) 1352-1353
107 Kim SJ, Lee HS, Kim HS. , et al. Outcome of video-assisted thoracoscopic surgery for spontaneous secondary pneumothorax. Korean J Thorac Cardiovasc Surg 2011; 44 (03) 225-228
108 Lee P. Primary spontaneous pneumothorax: to pleurodese or not?. Lancet 2013; 381 (9874): 1252-1254
109 Cao Gq, Kang J, Wang F, Wang H. Intrapleural instillation of autologous blood for persistent air leak in spontaneous pneumothorax in patients with advanced chronic obstructive pulmonary disease. Ann Thorac Surg 2012; 93 (05) 1652-1657
110 Davies HE, Mishra EK, Kahan BC. , et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307 (22) 2383-2389
111 Penz ED, Mishra EK, Davies HE, Manns BJ, Miller RF, Rahman NM. Comparing cost of indwelling pleural catheter vs talc pleurodesis for malignant pleural effusion. Chest 2014; 146 (04) 991-1000
112 Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006; 129 (02) 362-368
113 Wahidi MM, Reddy C, Yarmus L. , et al. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial. Am J Respir Crit Care Med 2017; 195 (08) 1050-1057
114 Boshuizen RC, Vd Noort V, Burgers JA. , et al. A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14). Lung Cancer 2017; 108: 9-14
115 Thomas R, Fysh ETH, Smith NA. , et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA 2017; 318 (19) 1903-1912
116 Bhatnagar R, Keenan EK, Morley AJ. , et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med 2018; 378 (14) 1313-1322
117 Sivakumar P, Douiri A, West A. , et al. OPTIMUM: a protocol for a multicentre randomised controlled trial comparing out patient talc slurry via indwelling pleural catheter for malignant pleural effusion vs usual inpatient management. BMJ Open 2016; 6 (10) e012795
118 Bhatnagar R, Kahan BC, Morley AJ. , et al. The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial. Trials 2015; 16: 48
119 Psallidas I, Piotrowska HEG, Yousuf A. , et al. Efficacy of sonographic and biological pleurodesis indicators of malignant pleural effusion (SIMPLE): protocol of a randomised controlled trial. BMJ Open Respir Res 2017; 4 (01) e000225